Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) insider Andrew Murphy sold 5,011 shares of the business's stock in a transaction dated Tuesday, November 17th. The stock was sold at an average price of $957.76, for a total transaction of $4,799,335.36. Following the transaction, the insider owned 46,779 shares in the company, valued at approximately $44,803,055.04. This trade represents a 9.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Regeneron Pharmaceuticals Stock Performance
REGN opened at $923.34 on Friday. The company has a market cap of $95.52 billion, a price-to-earnings ratio of 19.80, a PEG ratio of 1.25 and a beta of 0.10. The firm's fifty day simple moving average is $826.97 and its two-hundred day simple moving average is $751.27. The company has a quick ratio of 2.89, a current ratio of 3.35 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a 52-week low of $591.52 and a 52-week high of $991.73.
Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, topping analysts' consensus estimates of $16.51 by $3.56. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The firm had revenue of $5.12 billion for the quarter, compared to the consensus estimate of $4.58 billion. During the same quarter in the prior year, the company posted $11.83 earnings per share. The firm's revenue was up 36.3% on a year-over-year basis. Equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 58.26 earnings per share for the current fiscal year.
Regeneron Pharmaceuticals Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Shareholders of record on Friday, November 20th will be paid a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date is Friday, November 20th. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.30%.
Institutional Investors Weigh In On Regeneron Pharmaceuticals
Several large investors have recently bought and sold shares of REGN. BlackRock Inc. purchased a new position in Regeneron Pharmaceuticals during the 2nd quarter valued at about $5,682,636,000. Legal & General Group Plc acquired a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth about $473,872,000. Bank of New York Mellon Corp bought a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $472,950,000. Aberdeen Group plc raised its position in shares of Regeneron Pharmaceuticals by 560.7% during the third quarter. Aberdeen Group plc now owns 671,042 shares of the biopharmaceutical company's stock worth $508,831,000 after acquiring an additional 569,476 shares during the last quarter. Finally, Deutsche Bank AG bought a new position in Regeneron Pharmaceuticals during the 2nd quarter worth about $323,249,000. Hedge funds and other institutional investors own 83.31% of the company's stock.
Analyst Upgrades and Downgrades
A number of research analysts recently commented on the stock. Zacks Research raised shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Monday, September 28th. Bank of America raised their price target on shares of Regeneron Pharmaceuticals from $908.00 to $1,030.00 and gave the company a "buy" rating in a research note on Monday, November 2nd. Cantor Fitzgerald boosted their price target on shares of Regeneron Pharmaceuticals from $795.00 to $980.00 and gave the stock an "overweight" rating in a report on Monday, November 2nd. Evercore upped their price objective on shares of Regeneron Pharmaceuticals from $825.00 to $850.00 and gave the company an "outperform" rating in a research note on Friday, July 31st. Finally, Barclays raised their price objective on Regeneron Pharmaceuticals from $917.00 to $1,075.00 and gave the company an "overweight" rating in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and nine have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $904.41.
Get Our Latest Report on REGN
More Regeneron Pharmaceuticals News
Investors following REGN have been watching these news items:
- Positive Sentiment: The European Commission approved more flexible Libtayo dosing across six cancer indications. Less frequent infusions and shorter administration times could improve convenience and support use of Regeneron’s oncology drug. Libtayo dosing article
- Positive Sentiment: Regeneron plans to present new and updated data from its blood-disorder pipeline at the December ASH meeting, including potentially pivotal Ordspono data in marginal zone lymphoma and Lynozyfic data in AL amyloidosis. These updates may offer future growth opportunities, though they are not yet clinical or regulatory outcomes. ASH pipeline update
- Negative Sentiment: Livsayis will enter a market with established treatments from AstraZeneca and Argenx, so commercial uptake and competition will influence how much the approval adds to Regeneron’s results. Market competition article
About Regeneron Pharmaceuticals
(
Get Free Report)
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions. The company's medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Regeneron Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.
While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.